Halozyme Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M | $267.6M | $196.0M | $151.9M |
| Cost of Revenue | $228.8M | $159.4M | $192.4M | $139.3M | $81.4M | $43.4M | $45.5M | $10.1M |
| Gross Profit | $1.17B | $855.9M | $636.9M | $520.8M | $361.9M | $224.2M | $150.4M | $141.7M |
| Gross Margin | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% |
| Operating Expenses | ||||||||
| Research & Development | — | $79.0M | $76.4M | $66.6M | $35.7M | $34.2M | $140.8M | $150.3M |
| SG&A Expense | $207.1M | $154.3M | $149.2M | $143.5M | $50.3M | $45.7M | $77.3M | $60.8M |
| Operating Income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M | $-67.6M | $-69.3M |
| Operating Margin | 33.6% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.7% |
| Interest Expense | — | — | $18.8M | $16.9M | $7.5M | $20.4M | $11.6M | $18.0M |
| Pretax Income | $466.9M | $557.1M | $348.3M | $248.9M | $248.5M | $129.3M | $-72.3M | $-79.8M |
| Income Tax Expense | $150.0M | $113.0M | $66.7M | $46.8M | $-154.2M | $217.0K | $-11.0K | $537.0K |
| Net Income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M | $-72.2M | $-80.3M |
| Net Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% |
| EPS (Basic) | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 | $0.95 | $-0.50 | $-0.56 |
| EPS (Diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 |
| Shares Outstanding (Basic) | 119.8M | 126.8M | 131.9M | 136.8M | 140.6M | 136.2M | 144.3M | 143.6M |
| Shares Outstanding (Diluted) | 123.9M | 129.4M | 134.2M | 140.6M | 146.8M | 141.5M | 144.3M | 143.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |